Information  X 
Enter a valid email address

Synairgen plc (SNG)

  Print      Mail a friend       Annual reports

Friday 02 October, 2020

Synairgen plc

Appointment of Joint Broker

RNS Number : 8826A
Synairgen plc
02 October 2020
 

Synairgen plc

 

('Synairgen' or the 'Company')

 

Appointment of Joint Broker

 

Southampton, UK - 2 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the appointment of Numis Securities Limited as Joint Broker to the Company with immediate effect. finnCap remains Nominated Adviser and Joint Broker to the Company.

-Ends

 

For further enquiries, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap (Nominated Advisor & Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield

Tel: +44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media & Investor Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

[email protected]

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

 

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of

Southampton Professors Stephen Holgate, Donna Davies, and Ratko Djukanovic. The

business, focused primarily on lung viral defence in asthma, COPD, and COVID-19, uses its

differentiating human biology BioBank platform and world-renowned international academic

KOL network to discover and develop novel therapies for respiratory disease. Synairgen is

quoted on AIM (LSE: SNG). For more information about Synairgen, please see

https://www.synairgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPUASBRRSURRAA

a d v e r t i s e m e n t